BRAF and melanoma: Significant growth inhibition was observed in nearly all melanoma cell lines after exposure to LY3009120, suggesting its value for further in vitro and in vivo testing to target BRAF-resistant tumors and to study resistance mechanisms in comparative oncology [64].